Shijiazhuang Yiling Pharmaceutical (002603) Q3 2026 earnings summary

Executive summary

• Q3 revenue was ¥1.894bn, up 3.62% YoY; net income attributable to shareholders was ¥338.6m, up 2.04%.

• For 9M, revenue reached ¥5.968bn, up 1.72% YoY, while attributable net income rose 9.55% to ¥1.096bn.

Financial highlights

• 9M adjusted net income was ¥1.060bn, up 9.68% YoY; Q3 adjusted net income was ¥328.9m, up 1.17%.

• 9M non-recurring gains, net of tax and minority interests, totaled ¥35.95m; items included government grants and gains on financial assets.

• 9M operating cash flow increased 25.86% YoY to ¥1.609bn, primarily as sales collections increased.

Key financial ratios and metrics

• 9M basic and diluted EPS were both ¥0.6560, up 9.55% YoY; weighted average ROE was 9.73%, up 0.39 percentage points.

• Total assets were ¥14.153bn at quarter-end, up 3.49% from year-end; equity attributable to shareholders was ¥11.249bn, up 2.37%.